The current standard therapy for patients after diagnosis with late-stage non-small cell lung cancer (NSCLC) is treatment with programmed death receptor protien-1 (PD-1), or PD-L1 blockade alone or in combination with chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.